Chester County News and Community Website
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in the DUBSTENT DIABETES trial, a new clinical study designed to evaluate whether combining two …
Teleflex Launches Clinical Trial Testing Dual-Device Heart Procedure for Diabetic Patients Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received a key regulatory boost in its bid to bring a gene therapy for Stargardt disease to market, with the European Medicines …
Ocugen Gains EMA Backing for Single Pivotal Trial to Support Stargardt Disease Gene Therapy Approval Read More
WASHINGTON, D.C. — The U.S. Department of Health and Human Services (HHS) has announced a sweeping plan to wind down its mRNA vaccine development initiatives under the Biomedical Advanced Research …
HHS to Phase Out mRNA Vaccine Projects, Redirect Funding to Broader Platforms Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced encouraging top-line results from a Phase 2a trial evaluating ATI-2138, its oral investigational treatment targeting moderate-to-severe atopic dermatitis (AD). The study …
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration on Friday placed Sarepta Therapeutics’ gene therapy trials for limb girdle muscular dystrophy on clinical hold following the deaths of three patients …
FDA Shuts Down Sarepta Gene Therapy Trials After Three Deaths Linked to Liver Failure Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More
MALVERN, PA — In a major scientific advance, Progenra Inc. has announced the discovery of a novel class of small-molecule drugs designed to restore the function of mutant forms of …
Progenra Breakthrough Offers New Hope for Parkinson’s Disease and Beyond Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has initiated an immediate review of clinical trials involving the international transfer of Americans’ living cells for genetic engineering and subsequent …
FDA Investigates Clinical Trials Sending U.S. DNA Overseas Read More